STOCK TITAN
  1. Home
  2. News
  3. GNPX

Genprex Inc - GNPX STOCK NEWS

Welcome to our dedicated news page for Genprex (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genprex's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genprex's position in the market.

News
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Rhea-AI Summary
Genprex presents positive preclinical data for Reqorsa® Immunogene Therapy and NPRL2 gene therapy at AACR 2024, showcasing potential cancer treatments using Oncoprex® Delivery System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
clinical trial
-
News
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Rhea-AI Summary
Genprex, Inc. collaborates with a large network of oncology practices to open multiple clinical trial sites for its Acclaim-3 study on Reqorsa Immunogene Therapy in combination with Genentech's Tecentriq. The collaboration aims to accelerate patient enrollment, provide wider access to innovative treatments, and potentially benefit patients with small cell lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.51%
Tags
clinical trial
-
News
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Rhea-AI Summary
Genprex, Inc. announces positive preclinical data for NPRL2 gene therapy in KRAS/STK11 mutant NSCLC using Oncoprex® Delivery System. The therapy shows promising anti-tumor effects in a humanized mouse model, potentially offering a new treatment avenue for resistant NSCLC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
clinical trial
News
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Genprex, Inc. (GNPX) successfully closed a registered direct offering, raising approximately $6.5 million through the sale of 1,542,112 shares of common stock and warrants. The company intends to utilize the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
offering
-
News
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Genprex, Inc. (GNPX) announces a registered direct offering of common stock and warrants, totaling 1,542,112 shares, at a combined price of $4.215 per share. The warrants have an exercise price of $4.09 per share and expire five years from the date of issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.36%
Tags
offering
-
News
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Rhea-AI Summary
Genprex, Inc. announces the expansion of patents covering the use of REQORSA in combination with immune checkpoint inhibitors for cancer treatment. The Korean Patent Office granted a broad patent extending through 2037, applicable to Acclaim-2 and Acclaim-3 clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.43%
Tags
none
News
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Rhea-AI Summary
Genprex, Inc. announces positive preclinical data on REQORSA Immunogene Therapy and NPRL2 gene therapy for lung cancer at AACR 2024. Studies show promising results in inhibiting cancer cell growth and inducing anti-tumor immunity. Genprex's clinical trials for REQORSA in lung cancer have received FDA Fast Track Designation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.31%
Tags
conferences clinical trial
-
News
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
Rhea-AI Summary
Genprex, Inc. announces the expansion of its nonclinical programs into new indications through Sponsored Research Agreements and Material Transfer Agreements with multiple academic research collaborators. They are studying TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, REQORSA, and NPRL2, another tumor suppressor gene. The new indications being evaluated include ALK-positive lung cancer and other additional programs that are not disclosed at this time. Genprex's ONCOPREX® Nanoparticle Delivery System technology has been selected for a presentation at the 2024 AACR Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.17%
Tags
none
-
News
Genprex to Present at Upcoming BIO CEO & Investor Conference
Rhea-AI Summary
Genprex, Inc. will be presenting its gene therapies for cancer and diabetes at the upcoming BIO CEO & Investor Conference. The company's Chief Financial Officer, Ryan Confer, will provide an overview of the therapies and be available for one-on-one meetings with investors. The presentation will take place on Monday, Feb. 26, 2024, at 1:30 p.m. ET at The New York Marriott Marquis, Plymouth Room.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.45%
Tags
conferences
News
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Rhea-AI Summary
Genprex, Inc. expects to complete enrollment of Phase 2a expansion study by the end of 2024. The Acclaim-1 study has FDA Fast Track Designation. The company announced the enrollment and dosing of the first patient in the Phase 2a expansion portion of the Acclaim-1 clinical study of Reqorsa® Therapy in combination with AstraZeneca's Tagrisso® to treat patients with late-stage non-small cell lung cancer (NSCLC). The Phase 1 results demonstrated the combination was well tolerated with evidence of efficacy. Data from the Phase 1 portion of the clinical trial showed promising efficacy results, with extended progression free survival observed in patients. REQORSA, the lead product candidate, is being evaluated in three clinical trials as a treatment for NSCLC and SCLC, and has received Fast Track Designation and Orphan Drug Designation from the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.37%
Tags
clinical trial
Stock GNPX logo
Genprex Inc

Nasdaq:GNPX

GNPX Rankings

N/A Ranked by Market Cap
#5401 Ranked by Stock Gains
N/A Ranked by Dividends

GNPX Stock Data

5.12M
1.88M
0.85%
6.59%
3.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Austin

About GNPX

genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur